Document is current
Any future updates will be listed below
-
Authors
Depotte, Leonard
Nay, Paula
Borg, Christophe
Meurisse, Aurélia
Henriques, Julie
Bennouna, Jaafar
De La Fouchardière, Christelle
Tougeron, David https://orcid.org/0000-0002-8065-9635
Mazard, Thibault
Chibaudel, Benoist
Tournigand, Christophe
Vernerey, Dewi
Pigneur, Frédéric
Andre, Thierry https://orcid.org/0000-0002-5103-7095
Cohen, Romain https://orcid.org/0000-0001-9602-5162
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03350126 at ClinicalTrials.govnct04725474 at ClinicalTrials.govDocuments that mention this clinical trial
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study
https://doi.org/10.1136/jitc-2024-011220
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
https://doi.org/10.1136/jitc-2020-001499
nct06059547 at ClinicalTrials.govDocuments that mention this clinical trial
519 GDFATHER-01 trial longterm follow-up: GDF-15 neutralization combined with nivolumab can enable deep, longterm remission in heavily pretreated, anti-PD1/-L1 relapsed/refractory major solid tumor types
https://doi.org/10.1136/jitc-2025-sitc2025.0519
03.04 Targeted disruption of tumor-borne GDF-15-mediated immunoresistance restores immune checkpoint inhibitor activity in last-line cancer patients
https://doi.org/10.1136/jitc-2024-itoc10.2
568 Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment
https://doi.org/10.1136/jitc-2021-sitc2021.568
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study
https://doi.org/10.1136/jitc-2024-011220
Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.2513
1196 GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers
https://doi.org/10.1136/jitc-2023-sitc2023.1196
Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).
https://doi.org/10.1200/jco.2023.41.16_suppl.2501
504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)
https://doi.org/10.1136/jitc-2021-sitc2021.504
1049 SHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T-cells
https://doi.org/10.1136/jitc-2023-sitc2023.1049
P-01.16 GDF-15 inhibition overcomes treatment resistance to platinum-based chemoimmunotherapy
https://doi.org/10.1136/jitc-2025-itoc11.23
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences
https://doi.org/10.1136/gutjnl-2022-328428
Documents that mention this clinical trial
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study
https://doi.org/10.1136/jitc-2024-011220
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (N/A)
GERCOR (N/A)
- License Information
